The Novartis judgment took a very narrow view of Section 3(d), requiring a dramatic enhancement in therapeutic efficacy for a new form to be patentable. This has, frankly, made it difficult to secure rewards for incremental innovation that greatly improves patient compliance, like a stable crystal form. From my desk, reviewing drug portfolios, I see how this discourages local R&D investments in improved formulations. My tailoring shop's old motor reminds me daily that a small, practical improvement—a better bearing, a smoother stitch—has immense real value, even if the cloth is the same.
#athletics#track-and-field
Jump in to reply — no account needed.